AP2014007794A0 - Benzyl sulfonamide derivatives useful as mogat-2 inhibitors - Google Patents

Benzyl sulfonamide derivatives useful as mogat-2 inhibitors

Info

Publication number
AP2014007794A0
AP2014007794A0 AP2014007794A AP2014007794A AP2014007794A0 AP 2014007794 A0 AP2014007794 A0 AP 2014007794A0 AP 2014007794 A AP2014007794 A AP 2014007794A AP 2014007794 A AP2014007794 A AP 2014007794A AP 2014007794 A0 AP2014007794 A0 AP 2014007794A0
Authority
AP
ARIPO
Prior art keywords
mogat
inhibitors
derivatives useful
sulfonamide derivatives
benzyl sulfonamide
Prior art date
Application number
AP2014007794A
Other languages
English (en)
Inventor
Maria Carmen Fernandez
Lance Allen Pfeifer
Maria Rosario Gonzalez-Garcia
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47148691&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2014007794(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AP2014007794A0 publication Critical patent/AP2014007794A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/05—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
AP2014007794A 2012-01-31 2013-01-24 Benzyl sulfonamide derivatives useful as mogat-2 inhibitors AP2014007794A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261592717P 2012-01-31 2012-01-31
EP12382432 2012-11-06
PCT/US2013/022870 WO2013116075A1 (fr) 2012-01-31 2013-01-24 Dérivés de benzylsulfanilamide utilisés comme inhibiteurs -2 mogat

Publications (1)

Publication Number Publication Date
AP2014007794A0 true AP2014007794A0 (en) 2014-07-31

Family

ID=47148691

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2014007794A AP2014007794A0 (en) 2012-01-31 2013-01-24 Benzyl sulfonamide derivatives useful as mogat-2 inhibitors

Country Status (27)

Country Link
US (1) US8575352B2 (fr)
EP (1) EP2809651B1 (fr)
JP (1) JP2015511232A (fr)
KR (1) KR20140106750A (fr)
CN (1) CN104066719B (fr)
AP (1) AP2014007794A0 (fr)
AR (1) AR089771A1 (fr)
AU (1) AU2013215468A1 (fr)
BR (1) BR112014018636A8 (fr)
CA (1) CA2859995A1 (fr)
CL (1) CL2014001861A1 (fr)
CO (1) CO7010839A2 (fr)
CR (1) CR20140322A (fr)
DO (1) DOP2014000178A (fr)
EA (1) EA201491276A1 (fr)
ES (1) ES2590929T3 (fr)
GT (1) GT201400167A (fr)
HK (1) HK1199025A1 (fr)
IL (1) IL233712A0 (fr)
MA (1) MA35886B1 (fr)
MX (1) MX2014008599A (fr)
PE (1) PE20141679A1 (fr)
PH (1) PH12014501711A1 (fr)
SG (1) SG11201404106QA (fr)
TW (1) TW201343629A (fr)
WO (1) WO2013116075A1 (fr)
ZA (1) ZA201404836B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013112323A1 (fr) 2012-01-23 2013-08-01 Eli Lilly And Company Dérivés de phényle méthanesulfonamide utilisés comme inhibiteurs mgat - 2
ES2571577T3 (es) 2012-01-31 2016-05-26 Lilly Co Eli Derivados novedosos de morfolinilo útiles como inhibidores de MOGAT-2
EA201590696A1 (ru) 2012-11-06 2015-08-31 Эли Лилли Энд Компани Новые бензилсульфонамидные соединения, подходящие в качестве ингибиторов mogat-2
BR112017026739A2 (pt) 2015-06-15 2018-08-28 Nmd Pharma Aps compostos para uso no tratamento de distúrbios neuromusculares
TWI782056B (zh) 2017-07-14 2022-11-01 日商鹽野義製藥股份有限公司 具有ｍｇａｔ２抑制活性的縮合環衍生物
US11147788B2 (en) 2017-12-14 2021-10-19 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US11591284B2 (en) 2017-12-14 2023-02-28 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US10385028B2 (en) 2017-12-14 2019-08-20 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US11730714B2 (en) 2017-12-14 2023-08-22 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
BR112021012428A2 (pt) 2019-01-11 2021-09-08 Shionogi & Co., Ltd. Derivado de dihidropirazolopirazinona tendo atividade inibitória de mgat2

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1659113A1 (fr) * 2004-11-08 2006-05-24 Evotec AG Inhibiteurs de 11 beta hydroxy stéroid dehydrogenase type 1 (11beta-HSD1)
EP1655283A1 (fr) * 2004-11-08 2006-05-10 Evotec OAI AG Inhibiteurs de 11béta-HSD1
ATE404546T1 (de) * 2004-11-10 2008-08-15 Pfizer Substituierte n-sulfonylaminobenzyl-2- phenoxyacetamidverbindungen
CN101087771A (zh) * 2004-11-10 2007-12-12 辉瑞大药厂 经取代n－磺酰基氨基苄基－2－苯氧基乙酰胺化合物
MX2009002527A (es) * 2006-09-08 2009-03-20 Pfizer Prod Inc Derivados de eter diarilico y usos de los mismos.
EP2078719A4 (fr) * 2006-09-28 2009-11-11 Dainippon Sumitomo Pharma Co Composé ayant une structure de pyrimidine bicyclique et composition pharmaceutique comprenant le composé
KR20090064478A (ko) * 2006-11-13 2009-06-18 화이자 프로덕츠 인크. 디아릴, 디피리디닐 및 아릴-피리디닐 유도체, 및 이들의 용도
EP2219646A4 (fr) * 2007-12-21 2010-12-22 Univ Rochester Procédé permettant de modifier la durée de vie d'organismes eucaryotes
EP2398800A4 (fr) 2009-02-23 2012-07-25 Msd Kk Dérivés de pyrimidin-4(3h)-one
WO2013112323A1 (fr) 2012-01-23 2013-08-01 Eli Lilly And Company Dérivés de phényle méthanesulfonamide utilisés comme inhibiteurs mgat - 2
ES2571577T3 (es) 2012-01-31 2016-05-26 Lilly Co Eli Derivados novedosos de morfolinilo útiles como inhibidores de MOGAT-2

Also Published As

Publication number Publication date
EP2809651B1 (fr) 2016-06-29
EA201491276A1 (ru) 2014-10-30
IL233712A0 (en) 2014-09-30
AR089771A1 (es) 2014-09-17
BR112014018636A8 (pt) 2017-07-11
CN104066719B (zh) 2016-08-24
MA35886B1 (fr) 2014-12-01
TW201343629A (zh) 2013-11-01
ZA201404836B (en) 2017-08-30
HK1199025A1 (en) 2015-06-19
JP2015511232A (ja) 2015-04-16
CA2859995A1 (fr) 2013-08-08
CN104066719A (zh) 2014-09-24
CR20140322A (es) 2014-08-25
PE20141679A1 (es) 2014-11-08
US20130197039A1 (en) 2013-08-01
CO7010839A2 (es) 2014-07-31
PH12014501711A1 (en) 2014-10-13
MX2014008599A (es) 2014-08-22
US8575352B2 (en) 2013-11-05
SG11201404106QA (en) 2014-08-28
EP2809651A1 (fr) 2014-12-10
GT201400167A (es) 2015-05-28
ES2590929T3 (es) 2016-11-24
CL2014001861A1 (es) 2014-11-07
WO2013116075A1 (fr) 2013-08-08
KR20140106750A (ko) 2014-09-03
BR112014018636A2 (fr) 2017-06-20
DOP2014000178A (es) 2014-08-31
AU2013215468A1 (en) 2014-07-10

Similar Documents

Publication Publication Date Title
HUS2200040I1 (hu) Benzimidazol-prolin származékok
HK1210775A1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
ZA201305826B (en) Substituted amminobutyric derivatives as neprilysin inhibitors
HK1205740A1 (en) Pyrrolotriazinone derivatives
HK1199025A1 (en) Benzyl sulfonamide derivatives useful as mogat - 2 inhibitors mogat-2
HK1205508A1 (en) New bicyclicpyridine derivatives
EP2870140B8 (fr) Derives de tetrahydroquinazolinone comme inhibiteurs de parp
SG11201503447QA (en) Oxazolidin-2-one-pyrimidine derivatives
HK1209422A1 (en) Fbxo3 inhibitors fbxo3
PT2838883T (pt) Novos derivados de fenil-tetra-hidroisoquinolina
HK1199024A1 (zh) 可作為 抑制物使用之新型嗎啉基衍生物
ZA201502878B (en) Novel benzyl sulfonamide compounds useful as mogat-2 inhibitors